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Summary
 
T cell receptor (TCR) antagonism is being considered for inactivation of aggressive T cells and
reversal of T cell–mediated autoimmune diseases. TCR antagonist peptides silence aggressive T cells
and reverse experimental allergic encephalomyelitis induced with free peptides. However, it is
not clear whether free antagonist peptides could reverse natural disease where the antigen is pre-
sumably available for endocytic processing and peptides gain access to newly synthesized class II
MHC molecules. Using an efficient endocytic presentation system, we demonstrate that a pro-
teolipid protein (PLP) TCR antagonist peptide (PLP-LR) presented on an Ig molecule (Ig-
PLP-LR) abrogates the activation of T cells stimulated with free encephalitogenic PLP peptide
(PLP1), native PLP, or an Ig containing PLP1 peptide (Ig-PLP1). Free PLP-LR abolishes T cell
activation when the stimulator is free PLP1 peptide, but has no measurable effect when the
stimulator is the native PLP or Ig-PLP1. In vivo, Ig-PLP1 induces a T cell response to PLP1
peptide. However, when coadministered with Ig-PLP-LR, the response to PLP1 peptide is
markedly reduced whereas the response to PLP-LR is normal. Free PLP-LR coadministered with
Ig-PLP1 has no effect on the T cell response to PLP1. These findings indicate that endocytic
presentation of an antagonist peptide by Ig outcompete both external and endocytic agonist
peptides whereas free antagonist hinders external but not endocytic agonist peptide. Direct con-
tact with antagonist ligand and/or 
 
trans
 
-regulation by PLP-LR–specific T cells may be the op-
erative mechanism for Ig-PLP-LR–mediated downregulation of PLP1-specific T cells in vivo.
Efficient endocytic presentation of antagonist peptides, which is the fundamental event for ei-
ther mechanism, may be critical for reversal of spontaneous T cell–mediated autoimmune dis-
eases where incessant endocytic antigen processing could be responsible for T cell aggressivity.
 
O
 
ver the last few years it has become clear that the
avidity of T cell–APC interactions dictates thymic
learning and tolerance to self antigens (1). Accordingly,
high avidity interactions lead to elimination of the T cell,
whereas low avidity interactions allow for maturation and
exit from the thymus (2–4). Although this mechanism is ef-
fective in purging the immune system of autoreactivity, T cell
precursors endowed with self reactivity could still be gener-
ated if the autoantigen is sequestered and does not reach for
thymic presentation, is subjected to thymic crypticity, or is
poorly presented (5–7). Superantigens capable of reacting
with particular V
 
b
 
-TCR (8) and events that could set to
motion antigen mimicry (9), epitope spreading (10), or pe-
ripheral loosening in peptide crypticity (11), may trigger
activation of those self-reactive T cells and cause antigen
exposure. Continuous supply of autoantigen and abundant
generation of TCR ligands may be the mechanism of T cell
aggressivity. Multiple sclerosis (MS)
 
1
 
, type I diabetes, and
rheumatoid arthritis, all of which are thought to be T cell–
mediated autoimmune diseases qualify as examples of a spon-
taneous break of self tolerance (12–14).
Experimental allergic encephalomyelitis (EAE) that is used
as an animal model for MS can be induced in susceptible
strains of mice with myelin autoantigens such as proteolipid
protein (PLP) and myelin basic protein (MBP; for review
see reference 15). The encephalitogenic activity of these
proteins correlates with the presence of peptides that in-
duce in vivo class II–restricted encephalitogenic T cells and
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid; EAE, experimental allergic
encephalomyelitis; HA, hemagglutinin; MBP, myelin basic protein; MS,
multiple sclerosis; PLP, proteolipid protein; PLP1, the peptide corre-
sponding to aa residues 139-155 of PLP; PPD, purified protein derivative.
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consequently EAE (15). The peptide corresponding to amino
acid (aa) residues 139–151 of PLP (hereafter is referred to
PLP1) is encephalitogenic in H-2
 
s
 
 SJL mice (16), and T cell
lines specific for PLP1 transfer EAE into naive animals (17).
Although the target antigen(s) in human MS is still debat-
able, the frequency of T cells specific for myelin proteins
are higher in MS patients than in normal subjects (18–19).
Therefore, silencing those myelin-reactive T cells may be a
logical approach to reverse MS.
Interaction of T cells with altered peptide ligands could
have various effects on TCR-mediated effector functions (20).
These include induction of cytokine production without
proliferation (21), changes in the profile of cytokines pro-
duced (22), TCR antagonism that is a state of cytokine and
proliferative unresponsiveness (23–25), and anergy that is a
state of cytokine and proliferative unresponsiveness to a sub-
sequent stimulation with the agonist peptide (26). Peptide
analogues represent an attractive approach to modulating
the effector functions of aggressive T cells and ameliorating
autoimmune diseases. A promising success was achieved in
the EAE system in which mice induced for EAE with a free
MBP encephalitogenic peptide or by transfer of an MBP-
specific T cell clone recovered from the disease when they
were treated with a peptide analogue (27, 28). Similarly,
treatment of human T cells specific for MBP with a TCR
antagonist peptide modulated their cytokine production
profile and increased secretion of TGF-
 
b
 
 (22). Reversal of
EAE was also achieved with a TCR antagonist peptide de-
rived from PLP1 peptide (29). Indeed, when the major
TCR contacting residues within PLP1 were mutated, the re-
sulting peptide analogue (hereafter referred to as PLP-LR),
although binding to I-A
 
s
 
 equally as well as PLP1, does not
activate PLP1-specific T cells. Instead, PLP-LR inhibits in
vitro activation of the T cells by PLP1. In addition, EAE
induced in mice with free PLP1 peptide resolved after
treatment with free PLP-LR (29). Since only a few MHC–
peptide complexes are available on the surface of APCs,
and a single complex may be required to serially trigger
 
z
 
200 TCRs to activate the T cells (30, 31), the ratio of an-
tagonist versus agonist ligands on the surface of a given
APC becomes a major factor as to whether injection of free
peptide analogues could reverse spontaneous autoimmune
disease where the autoantigen could be continuously avail-
able. Furthermore, the presentation of autoantigens may oper-
ate through an endocytic pathway loading peptides onto
newly synthesized MHC molecules and generating an un-
surmountable agonist–MHC target to overcome. Overcom-
ing such obstacles may demand highly effective antagonist
systems. One such approach might well be peptide presen-
tation on autologous Ig. Ig can function as a delivery sys-
tem for T cell peptides (32, 33). A 100–1,000-fold increase
in T cell activation was observed when a class II–restricted
peptide from the hemagglutinin (HA) of influenza virus was
presented on an Ig chimera, Ig-HA (34). Similar results
were obtained when a class II peptide from 
 
l
 
2
 
 phage re-
pressor protein was expressed on an IgG1 molecule (35).
The increase in T cell activation appears to result from effi-
cient peptide loading onto MHC molecules (36).
In the present report, we asked whether Ig-mediated en-
docytic presentation of an antagonist peptide could out
compete high endosomal antigen load and downregulate
autoreactive T cells. To this end, PLP-LR antagonist pep-
tide was expressed on an Ig molecule and the resulting Ig–
PLP-LR chimera was compared with free PLP-LR for an-
tagonism of PLP-specific T cells. The results indicate that
Ig-PLP-LR inactivates PLP1-specific T cells whether the
stimulator is PLP1 peptide, native PLP, or even an Ig ex-
pressing PLP1 (Ig-PLP1). However, a free PLP-LR pep-
tide could not inhibit IL-2 production when the T cells were
stimulated with APCs pulsed with Ig-PLP1 or native PLP.
In vivo, when Ig-PLP1 was administered to SJL/J mice it in-
duced a strong PLP1-specific T cell response, but when
coadministered with Ig-PLP-LR, the response to PLP1 fell
to almost background levels. Efficient endocytic presenta-
tion of antagonist peptides may therefore oppose the un-
limited and persistent generation of endogenous self pep-
tides that might occur in T cell–mediated autoimmune
diseases such as MS.
 
Materials and Methods
 
Animals
 
6–8-wk-old SJL/J mice (H-2
 
s
 
) were purchased from Harlan
Sprague Dawley (Frederick, MD) and maintained in our animal
facility for the duration of experiments. New Zealand white rabbits
were purchased from Myrtle’s Rabbitry (Thompson Station, TN).
 
Antigens
 
Peptides.
 
All peptides used in these studies were purchased
from Res. Genetics (Huntsville, Alabama) and purified by HPLC
to 
 
.
 
90% purity. PLP1 peptide (HSLGKWLGHPDKF) encom-
passes an encephalitogenic sequence corresponding to aa residues
139–151 of PLP (16). PLP-LR (HSLGK
 
L
 
LG
 
R
 
PDKF) is a mu-
tant form of PLP1 in which Trp144 and His147 were replaced
with Leu and Arg, respectively (29). PLP1 and PLP-LR bind
equally well to I-A
 
s
 
 class II molecules (29). However, stimulation
of T cell hybridomas with PLP1 in the presence of PLP-LR leads
to blockade of IL-2 production by these T cells (29). PLP2 pep-
tide (NTWTTCQSIAFPSK) encompasses an encephalitogenic
sequence corresponding to aa residues 178–191 of PLP (37). This
peptide binds to I-A
 
s
 
 class II molecules and induces EAE in SJL/J
mice (37). HA110-120 peptide corresponds to aa residues 110–
120 of the HA of influenza virus. HA110-120 binds to I-E
 
d
 
 class
II molecules and is used here as control peptide (34).
 
Ig-PLP Chimeras.
 
PLP1 and PLP-LR peptides were expressed
on Ig chimeras that were designated Ig-PLP1 and Ig-PLP-LR, re-
spectively. The genes used to construct these chimeras are those
coding for the light (38) and heavy (39) chains of the anti-arson-
ate antibody, 91A3. The procedures for deletion of the heavy chain
CDR3 region and replacement with nucleotide sequences coding
for PLP1 and PLP-LR are similar to those described for the gen-
eration of Ig-NP (40), a chimera carrying a CTL epitope corre-
sponding to aa residues 147–161 of the nucleoprotein of PR8 in-
fluenza A virus. In brief, the 91A3V
 
H
 
 gene was subcloned into
the EcoRI site of pUC19 plasmid and used as template DNA in
PCR mutagenesis reactions (40) to generate 91A3V
 
H
 
 fragments
carrying PLP1 (91A3V
 
H
 
-PLP1) and PLP-LR (91A3V
 
H
 
-PLP-
LR) sequences in place of CDR3. Nucleotide sequencing analysis
indicated that full PLP1 and PLP-LR sequences were inserted in 
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the correct reading frame (not shown). The 91A3V
 
H
 
-PLP1 and
91A3V
 
H
 
-PLP-LR fragments were then subcloned into the
EcoRI site of pSV2-gpt-C
 
g
 
2b in front of the exons coding for
the constant region of a BALB/c 
 
g
 
2b that generated pSV2-gpt-
91A3V
 
H
 
-PLP1-C
 
g
 
2b and pSV2-gpt-91A3V
 
H
 
-PLP1-LR-C
 
g
 
2b plas-
mids, respectively. These plasmids were then separately co-trans-
fected into the non-Ig–producing SP2/0 B myeloma cells with an
expression vector carrying the parental 91A3 light chain, pSV2-
neo-91A3L (38, 40). Transfectants producing Ig chimeras were
selected in the presence of geneticin and mycophenolic acid.
Transfectants were cloned by limiting dilution, and final clones
secreted 1–4 
 
m
 
g/ml of Ig-PLP chimeras. All the cloning, sequencing,
and purification procedures are similar to those used to generate Ig-
NP (40) and Ig-HA (34). Nucleotide sequences and detailed mu-
tagenesis procedures for Ig-PLP1 and Ig-PLP-LR will be published
elsewhere. Also used in these studies was Ig-W (40), a chimera
encoded by wild-type genes that does not carry any PLP peptide.
Large scale cultures of transfectants were carried out in DMEM
containing 10% iron enriched calf serum (Intergen Corp., Pur-
chase, New York). Ig-PLP chimeras were purified from culture
supernatant on columns made of rat anti–mouse 
 
k
 
 chain coupled
to CNBr activated Sepharose 4B (Pharmacia). To avoid cross-
contamination, separate columns were used to purify the chimeras.
 
PLP.
 
PLP was purified from rat brain according to a previ-
ously described procedure (41). In brief, the brain was homoge-
nized in 2:1 vol/vol chloroform/methanol, and the soluble crude
lipid extract was separated by filtration through a scintered glass
funnel. PLP was then precipitated with acetone and the pellet was
redissolved in a mixture of chloroform, methanol, and acetic acid
and passed through a sephadex column (LH-20-100; Sigma Chem-
ical Co., St. Louis, MO) to remove residual lipids. Removal of
chloroform from the eluates and conversion of PLP into its apo-
protein form were carried out simultaneously through gradual ad-
dition of water under a gentle stream of nitrogen. Subsequently,
extensive dialysis against water was performed to remove residual
acetic acid and methanol.
 
Production of Rabbit Anti–peptide Antibodies
 
PLP1 and PLP-LR peptides were coupled to KLH and BSA as
described (42). Rabbits were immunized with 1 mg peptide–
KLH conjugates in CFA and challenged monthly with 1 mg con-
jugate in IFA until a high antibody titer was reached as described
(43). The peptide–BSA conjugates were coupled to Sepharose and
used to purify anti–peptide antibodies from the rabbit antiserum.
 
Radioimmunoassay
 
Capture radioimmunoassay was used to assess expression of
PLP peptides on Ig. Microtiter 96-well plates were coated with
rabbit anti–peptide antibodies (5 
 
m
 
g/ml) overnight at 4
 
8
 
C and
blocked with 2% BSA in PBS for 1 h at room temperature. The
plates were then washed three times with PBS, and graded amounts
of Ig-PLP chimeras were added and incubated for 2 h at room
temperature. After three washes with PBS, captured Ig-PLP chi-
meras were revealed by incubating the plates with 10
 
5
 
 cpm/well
 
125
 
I-labeled rat anti–mouse 
 
k
 
 mAb for 2 h at 37ºC. The plates
were then washed five times with PBS and counted using an LKB
gamma counter.
 
Cells
 
PLP1-specific T cell hybridomas 5B6 and 4E3 (29) and the IL-2–
dependent HT-2 T helper were obtained from Drs. M.B. Lees
and V. Kuchroo (The Eunice Kennedy Shriver Center, Wal-
tham, MA). The 5B6 and 4E3 T cells recognize PLP1 in associa-
tion with I-A
 
s
 
 and produce IL-2 in response to it (29). However,
when stimulated with PLP1 and then with PLP-LR, they be-
come unable to produce IL-2 (29). The rat anti–mouse 
 
k
 
 chain
mAb (187.1 or American Type Culture Collection denotation,
HB-58) and the mouse anti–rat 
 
k
 
 light chain mAb (MAR 18.5 or
American Type Culture Collection denotation TIB 216) were
obtained from American Type Culture Collection (Rockville,
MD). These hybridomas were grown to large scale and purified
from culture supernatant on each other. The rat anti–mouse 
 
k
 
mAb was used to prepare columns on which Ig-PLP chimeras
were purified from culture supernatant.
 
T Cell Activation Assay
 
Irradiated (3,000 rads) SJL splenocytes (used as APCs) were in-
cubated in 96-well round-bottom plates (5 
 
3
 
 10
 
5
 
 cells/well/50 
 
m
 
l)
with graded concentration of antigens (100 
 
m
 
l/well). After 1 h, T
cell hybridomas (5 
 
3
 
 10
 
4
 
 cells/well/50 
 
m
 
l) were added and the
culture was continued overnight. Activation of the T cells was as-
sessed by measuring production of IL-2 in the culture superna-
tant. This was done by [
 
3
 
H]thymidine incorporation using the
IL-2–dependent HT-2 cells. In brief, culture supernatants (100
 
m
 
l/well) were incubated with HT-2 cells (10
 
4
 
/100 
 
m
 
l/well) in
96-well flat-bottom plates for 24 h. Subsequently, 1 
 
m
 
Ci [
 
3
 
H]thy-
midine was added per well and the culture was continued for an
additional 12–14 h. The cells were then harvested on glass fiber
filters, and incorporated [
 
3
 
H]thymidine was counted using the
trace 96 program and an Inotech 
 
b
 
 counter. The culture media
used to carry out these assays were DMEM supplemented with
10% FBS, 0.05 mM 2-mercaptoethanol, 2 mM glutamine, 1 mM
sodium pyruvate, and 50 
 
m
 
g/ml gentamycin sulfate.
 
Assay for Inhibition of T Cell Activation
 
Irradiated (3,000 rads) SJL/J splenocytes (used as APCs) were
incubated in 96-well round-bottom plates (5 
 
3
 
 10
 
5
 
 cells/well/50 
 
m
 
l)
with the stimulator antigen (optimal dose in 50 
 
m
 
l/well) and
graded concentration of inhibitor (100 
 
m
 
l/well) for 1 h. Subse-
quently, T cell hybridomas (5 
 
3
 
 10
 
4
 
 cells/well/50 
 
m
 
l) were
added and the culture was continued overnight. IL-2 production
in the supernatant, which was used as measure of T cell activa-
tion, was determined using HT-2 cells, as above.
 
Immunization of Mice with Ig Chimeras and Peptides
 
Immunization with Ig-PLP1.
 
Mice were immunized subcuta-
neously in the foot pads and at the base of the limbs and tail with
50 
 
m
 
g of Ig-PLP1 emulsified in a 200 
 
m
 
l mixture 1:1 vol/vol
PBS/CFA. 10 d later the mice were killed by cervical dislocation,
the spleens and lymph nodes (axillary, inguinal, popliteal, and sac-
ral) were removed, single cell suspensions were prepared, and the
T cell responses were analyzed as described below.
 
Co-immunization of Mice with Ig-PLP1 and Ig-PLP-LR, Ig-W, or
PLP-LR peptide.
 
Individual mice from three groups (four mice
per group) were injected subcutaneously as above with a 200 
 
m
 
l
mixture (PBS/CFA, 1:1 vol/vol) containing 50 
 
m
 
g Ig-PLP1 and
150 
 
m
 
g Ig-PLP-LR; 50 
 
m
 
g Ig-PLP1 and 150 
 
m
 
g Ig-W; or 50 
 
m
 
g
Ig-PLP1 and 100 
 
m
 
g PLP-LR peptide. Splenic and lymph node
T cell responses were analyzed at day 10 after immunization.
 
Assays for Spleen and Lymph Node Proliferative Responses
 
Lymph node and spleen cells were incubated in 96-well round-
bottom plates at 4 and 10 
 
3
 
 10
 
5
 
 cells/100 
 
m
 
l/well, respectively,
with 100 
 
m
 
l of stimulator for 3 d. Subsequently, 1 
 
m
 
Ci [
 
3
 
H]thy- 
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midine was added per well, and the culture was continued for an
additional 12–14 h. The cells were then harvested on glass fiber
filters, and incorporated [
 
3
 
H]thymidine was counted using the
trace 96 program and an Inotech 
 
b
 
 counter. The stimulators were
used at the following concentrations: PLP1, PLP2, and PLP-LR
peptides at 15 
 
m
 
g/ml, and proteolipid protein (PPD) at 5 
 
m
 
g/ml.
A control media with no stimulator was included for each mouse
and used as background.
 
Results
 
Expression of PLP Peptides on Ig Molecules.
 
Two Ig-PLP
chimeras designated Ig-PLP1 and Ig-PLP-LR were con-
structed to include PLP1 and PLP-LR peptides, respec-
tively (Fig. 1). In both cases, the heavy chain CDR3 loop
was deleted and replaced with nucleotide sequences coding
for the selected peptide. DNA sequencing analysis indi-
cated insertion of peptide nucleotide sequences in the cor-
rect reading frame (not shown). In addition, rabbit anti-
bodies to synthetic PLP1 and PLP-LR peptides recognized
the chimeras (Fig. 2). Indeed, when Ig-PLP1 and Ig-PLP-
LR were incubated on plates coated with rabbit anti-PLP1
antibodies they were captured by these rabbit antibodies
and bound 
 
125
 
I-labeled rat anti–mouse 
 
k
 
 chain mAb (Fig. 2 
 
a
 
).
Similarly, both Ig-PLP1 and Ig-PLP-LR were captured by
rabbit anti–PLP-LR (Fig. 2 
 
b
 
). Ig-W, the wild-type 91A3
antibody without peptide and an IgM control antibody, did
not show significant binding to the rabbit antibodies. Ig-
PLP1 bound to both anti-PLP1 and anti-PLP-LR antibod-
ies better than did Ig-PLP-LR, indicating that structural
differences affected accessibility of the peptides to the rabbit
antibodies. The above experiments also indicated that pep-
tide expression on the chimeras did not alter heavy and light
chain pairing because the rabbit antibodies bind to the PLP
peptide on the heavy chain and the rat anti-
 
k
 
 binds on the
light chain.
 
Presentation of Ig-PLP Chimeras to T Cells.
 
The CDR3
of the 91A3 Ig is permissive for peptide expression, and both
class I– and class II–restricted epitopes have been efficiently
processed and presented to T cells when grafted in place of
the D segment (34, 40). Ig-PLP1 that includes the PLP1
peptide within CDR3 is also presented to specific T cells
(Fig. 3). T cell hybridomas 5B6 and 4E3 specific for PLP1
produced IL-2 subsequent to stimulation with APCs pulsed
with Ig-PLP1 as they have done when pulsed with PLP1
and native PLP. The negative controls Ig-W, Ig-HA, and
PLP2 peptide did not induce the production of IL-2 by the
T cells. Both Ig-PLP-LR and PLP-LR peptide do not
stimulate 5B6 and 4E3 for production of IL-2 (Fig. 3).
These results are expected because PLP-LR peptide is known
to negate rather than stimulate IL-2 production. However,
whereas these experiments could not show the processing
and presentation of Ig-PLP-LR, we have evidence that
PLP-LR peptide is released from the chimeras and pre-
sented to the T cells (see below).
 
Efficient Presentation of Ig-PLP1 to T Cells.
 
In spontane-
ous disease, exposure and continuous endocytic presentation
of autoantigen may generate significant levels of MHC–ago-
nist complexes. Ig-PLP1 was constructed for the purpose of
Figure 1. Schematic representation of Ig-PLP1 and Ig-PLP-LR. The
CDR3 loop (D segment) of the heavy chain variable region of the antiar-
sonate antibody 91A3, was deleted and replaced with nucleotide se-
quences that encode PLP1 and PLP-LR peptides. These chimeric VH
genes were then ligated to a gene encoding a BALB/c g2b constant re-
gion to generate complete chimeric heavy chain. These heavy chains were
then co-transfected with parental 91A3 k light chain into the non-Ig–
secreting myeloma cell SP2/0 to generate a complete IgG2b,K chimera
carrying PLP1 (Ig-PLP1) and PLP-LR (Ig-PLP-LR) peptide. Other chi-
meras were also used as controls: Ig-HA, an Ig molecule carrying in place
of the D segment the HA110-120 T helper epitope from the HA and dif-
fer  from Ig-PLP1 and Ig-PLP-LR only by the peptide inserted within
CDR3. Ig-W is the product of unmodified (wild-type) 91A3VH gene,
BALB/c g2b constant region, and 91A3 k light chain. Therefore, it dif-
fers from Ig-PLP1 and Ig-PLP-LR in the CDR3 region which is the pa-
rental D segment. Ig-PLP2 is a chimera that carries aa residues 178–191 of
PLP (this chimera will be described elsewhere) within the heavy chain
CDR3 loop.
Figure 2. PLP peptide expression on Ig-PLP1 and Ig-PLP-LR. Rabbit
antibodies to PLP1 and PLP-LR were used in a capture radioimmunoas-
say to demonstrate peptide expression on the chimeras. Micotiter plates
were coated with affinity-purified rabbit antibodies to PLP1 (a) or to
PLP-LR (b), blocked with BSA, and incubated with graded amounts (27,
9, 3, and 1 mg/ml) of Ig-PLP1, Ig-PLP-LR, or negative control Ig-W.
Captured Ig were revealed with 125I-labeled rat anti–mouse k light chain
mAb. Shown are the mean 6 SD of triplicates obtained with 27 mg/ml of
chimeras.1047 Legge et al.
establishing a peptide delivery system that could efficiently
operate through the endocytic pathway and generate high
levels of agonist ligands such that it provides a relevant sys-
tem to investigate T cell antagonism in a situation similar to
presentation of autoantigens. It is therefore important to
determine the efficacy of Ig-PLP1 in peptide delivery and
presentation to specific T cells. To this aim, dose response
T cell activation assays were performed with free PLP1
peptide, native PLP, and Ig-PLP1. The results shown in
Fig. 4 indicate that the PLP1 T cell epitope was better pre-
sented by Ig-PLP1 than by native PLP or by free PLP1
peptide. Although the plateau of IL-2 production was
higher when the T cell stimulator is PLP1 synthetic pep-
tide, the individual half maximal IL-2 production by the
T cells required about 100-fold higher of PLP or PLP1 pep-
tide than Ig-PLP1 (Fig. 4). The efficacy of Ig-PLP1 in pep-
tide delivery may be related to FcR-mediated internaliza-
tion and access to newly synthesized MHC molecules, as
we have previously shown for Ig-HA (34, 36), whereas
PLP may internalize by simple fluid phase pinocytosis, and
PLP1 peptide may bind to empty MHC class II molecules
at the cell surface. Overall, Ig-PLP1 is efficient in loading
PLP1 peptide onto class II molecules within the endosomal
compartment.
Inhibition of T Cell Activation by Ig-PLP-LR. The potency
of Ig-PLP1 chimeras in peptide loading onto class II mole-
cules provides a situation that probably resembles in vivo
autoimmune circumstances, where a continuous supply of
antigen may allow for abundant generation of self peptides,
which could trigger T cells aggressively. The Ig-PLP1 en-
docytic presentation system was then used to investigate Ig-
PLP-LR for inactivation of PLP1-specific T cells. As shown
in Fig. 5 a, when T cells were incubated with APCs in the
presence of both PLP1 and Ig-PLP-LR, a specific decrease
in IL-2 production occurred as the concentration of Ig-
PLP-LR increased. These results are in agreement with a
previous report that showed that efficient endocytic pre-
sentation of an antagonist form of hemoglobin outcom-
peted an external agonist peptide (44). A similar decline in
IL-2 production was evident when the synthetic PLP-LR
Figure 3. Presentation of Ig-
PLP chimeras to PLP1-specific T
cell hybridomas. Ig-PLP1 and
Ig-PLP-LR were assayed for
presentation to the PLP1-specific
T cell hybridomas 4E3 (a) and
5B6 (b) by measurement of IL-2
production as indicated in the
Materials and Methods section.
Irradiated SJL/J splenocytes (as
APCs) were incubated with the
indicated antigens and T cells
overnight, and IL-2 content of
the supernatant was measured
by [3H]thymidine incorporation
using the IL-2–dependent HT-2
cells. The concentration of anti-
gen was 0.1 mM for Ig-PLP1,
Ig-PLP-LR, Ig-HA, and Ig-W;
1 mM for PLP1 and PLP2 pep-
tides; and 1.7 mM for PLP. Each
value represents the mean 6 SD
of triplicate wells.
Figure 4. Efficient presentation of Ig-PLP1 to 4E3 T cell hybridoma.
Graded amounts of each antigen were incubated with splenic SJL/J APCs
and the PLP1-specific 4E3 T cell hybridoma, and IL-2 production was
measured by [3H]thymidine incorporation using the IL-2–dependent HT-2
cells as described in the legend to Fig. 3. Each point represents the mean
of triplicates. The SD did not exceed 10% of the mean value. Although
the maximal activation varied among the three different stimulators, the
individual half maximal activation required less Ig-PLP1 (0.005 mM) than
PLP (0.5 mM) or PLP1 peptide (0.6 mM).1048 Broad T Cell Antagonism by Endocytic Presentation of a Peptide Analogue
peptide was used during T cell activation with PLP1 pep-
tide. Antagonistic effects were not observed with Ig-W
chimera and PLP2 peptide used as negative controls (Fig. 5
a). The half maximal inhibition of IL-2 production (60%
control thymidine incorporation) required 0.4 mM Ig-PLP-
LR versus 9 mM PLP-LR peptide indicating a much more
efficient presentation of and consequently T cell antago-
nism by Ig–PLP-LR (Fig. 5 a).
Further evidence that the chimera is more efficient than
the free peptide in T cell antagonism is shown in Fig. 5, b
and c. Ig-PLP-LR inhibited T cell activation mediated by
Ig-PLP1 (Fig. 5 b) whereas free PLP-LR did not show any
significant antagonism like the negative control PLP2 pep-
tide (Fig. 5 b). Ig-W, the wild-type 91A3 Ig without pep-
tide, showed partial inhibitory activity in Ig-PLP1–medi-
ated T cell activation (Fig. 5 b). This is likely the result of
competition for binding to the FcR on APCs because both
Ig-PLP1 and Ig-W share identical IgG2b constant regions.
As the concentration of Ig-W increases, less Ig-PLP1 will
bind to FcR and internalize into the APCs, resulting in a
diminished presentation and IL-2 production. Ig-W had
similar inhibitory effects on the presentation of Ig-HA, as
did the anti-FcR mAb 2.4G2 (34). Finally, Ig-PLP-LR,
but not Ig-W, abolished the activation of T cells by native
PLP (Fig. 5 c). However, PLP-LR and the negative control
PLP2 peptide did not inhibit PLP-mediated T cell activa-
tion.
Competition for binding to class II molecules seems not
to be the operative mechanism of antagonism at the en-
docytic level. This conclusion is drawn from the observa-
tion that Ig-PLP2, a chimera carrying PLP2 peptide (Min,
B., K.L. Legge, and H. Zaghouani, manuscript in prepara-
tion), did not inhibit PLP-mediated T cell activation (Fig.
6) even though Ig-PLP2 is presented by I-As like PLP1.
In Vivo Antagonism of PLP1-specific T Cells by Ig-PLP-
LR. As demonstrated in Fig. 7, when individual mice
were immunized with Ig-PLP1, they developed strong
PLP1-specific T cell responses in the lymph nodes (Fig. 7 a)
and even significant proliferation in the spleen (Fig. 7 b).
Consequently, Ig-PLP1, which is presumably processed in
endocytic vacuoles like autoantigens, provides a relevant
system to assay the antagonists Ig-PLP-LR and PLP-LR
peptide for in vivo T cell antagonism.
The results in Fig. 8 indicate that co-immunization of
mice with Ig-PLP1 and Ig-PLP-LR led to a reduced T cell
Figure 5. Antagonism of PLP1–, PLP–, and Ig-PLP1–mediated T cell
activation by Ig-PLP-LR. SJL/J splenic APCs were incubated with (a) 1 mM
PLP1 peptide, (b) 0.05 mM Ig-PLP1, or (c) 6.8 mM PLP in the presence
of graded amounts of antagonists or controls antigens, and then assayed
for activation of the PLP1-specific T cell hybridoma 4E3, by measuring
IL-2 production as described in the Materials and Methods section. The
antagonists were Ig-PLP-LR (squares), PLP-LR (circles), and the controls were
Ig-HA (diamonds) and PLP2 (triangles). The cpm value obtained when the
APCs were incubated with the stimulator but no antagonist was used as
maximum [3H]thymidine incorporation. This value was 7,503 6 1,302
for Ig-PLP1; 31,089 6 3,860 for PLP1; and 8,268 6 915 for PLP. The
cpm value obtained when the APCs were incubated with no stimulator
and no antagonist was used as background (BG). This value was 1,560 6
323 for Ig-PLP1; 2,574 6 290 for PLP1; and 2,127 6 177 for PLP. The
percent control thymidine incorporation was calculated as follows: (cpm ob-
tained in the presence of test antagonist 2 BG)/(cpm control thymidine in-
corporation value 2 BG). Each point represents the mean of triplicates.
Figure 6. Competition for binding to class II at the endocytic level is
not the mechanism for Ig-PLP-LR–mediated antagonism. SJL/J splenic
APCs were incubated with native PLP (6.8 mM) in the presence of 50
mg/ml (0.3 mM) Ig-PLP2, Ig-PLP-LR, or Ig-W and 5 3 104 PLP1-spe-
cific 4E3 T cells. IL-2 production was assessed by [3H]thymidine incorpo-
ration using HT-2 cells as described in the legend to Fig. 5. The percent
control [3H]thymidine incorporation was calculated as in Fig. 5. Each col-
umn represents the mean 6 SD of triplicates.1049 Legge et al.
response to PLP1 when compared to responses obtained in
mice injected with Ig-PLP1/Ig-W mixture. Both lymph
node (Fig. 8 a) and splenic (Fig. 8 b) T cell responses were
markedly reduced as a consequence of coadministration of
Ig-PLP-LR with Ig-PLP1.
Because Ig-PLP-LR could induce a T cell response to
PLP-LR, lymph node and spleen cells from mice immu-
nized with Ig-PLP1/Ig-PLP-LR mixture were stimulated
in vitro with PLP-LR peptide, and the specific [3H]thymi-
dine incorporation was measured and compared with PLP1
specific proliferation. The results depicted in Fig. 9 indicate
that PLP-LR–specific T cells were present in both the
lymph nodes (Fig. 9 a) and spleen (Fig. 9 b), and the spe-
cific proliferation to PLP-LR was two- to nine-fold higher
than the proliferation to PLP1.
Mice co-immunized with Ig-PLP1 and free PLP-LR
peptide showed no evidence for reduction of PLP1-specific
responses (Table 1). To minimize the role of individual and
experimental intrinsic variability on the overall outcome of
the in vivo experiments, the PLP1-specific proliferations
were expressed as percent of the individual response to
PPD (Table 1). The standardized results clearly indicated a
fall in the PLP1-specific response in the mice injected with
Ig-PLP1 and Ig-PLP-LR relative to those injected with Ig-
PLP1/Ig-W or Ig-PLP1/ PLP-LR peptide mixtures.
Discussion
Herein, we designed an endocytic antigen presentation
system and evaluated fundamental mechanisms as to whether
TCR antagonist peptides could overcome antigens that be-
cause of efficient supply and access to endocytic processing
could generate high levels of encephalitogenic peptides and
therefore MHC–agonist complexes. In this system, PLP1
peptide and a TCR antagonist form of it, PLP-LR, were
expressed on the anti-arsonate antibody 91A3, and the re-
sulting Ig-PLP1 and Ig-PLP-LR chimeras were used to
evaluate T cell antagonism in an antigen system requiring
endocytic processing as it might occur in natural autoim-
Figure 7. In vivo priming of PLP1-specific T cells by Ig-PLP1. Mice
were immunized subcutaneously with 50 mg of Ig-PLP1 in CFA as de-
scribed in Materials and Methods, and after 10 d, cells from the lymph
nodes (a) and spleen (b) were tested for specific proliferation to PLP1. The
indicated results are those obtained with 4 3 105 lymph node cells/well
and 10 3 105 spleen cells/well. The stimulators PLP1 and PLP2 were
used at 15 mg/ml and PPD was used at 5 mg/ml. Each value represents
the mean 6 SD of triplicates after deduction of BG cpms obtained with
no stimulator in the media. The cpm values obtained with PPD for each
mouse exceeded the cpm values obtained with PLP1 by 20–60% depen-
dent upon each mouse. Similar results were obtained when mice were
immunized with 150 mg of Ig-PLP1 per mouse (not shown). Note that
some mice show proliferation with PLP2. This may be because this pep-
tide is presented by I-As, like PLP1, and low affinity cells could bind to it.
Figure 8. Coadministration of Ig-PLP-LR with Ig-PLP1 reduces the
response to PLP1 peptide. Mice were co-immunized with 50 mg Ig-PLP1
and 150 mg Ig-PLP-LR or 50 mg Ig-PLP1 and 150 mg Ig-W as indicated
in Materials and Methods. The lymph node (a) and splenic (b) prolifera-
tive responses to PLP1 peptide were analyzed 10 d later. The lymph node
cells were used at 4 3 105 cells/well and the spleen cells at 106 cells per
well. The stimulators were PLP1 (15 mg/ml), and PPD (5 mg/ml). The
indicated results are those obtained with PLP1 peptide and represent the
mean 6 SD of triplicates after deduction of BG cpm obtained with no
stimulator in the media. The cpm values obtained with PPD were similar
in both groups of mice and were 5–30% higher than the cpm values ob-
tained with PLP1 in the mice immunized with Ig-PLP1 and Ig-W.
Figure 9. Mice co-injected with Ig-PLP1 and Ig-PLP-LR develop
higher proliferative response to PLP-LR than PLP1 peptide. Day 10 after
immunization, lymph node (a) and splenic (b) proliferative responses to
PLP-LR peptide, in mice that were co-injected with Ig-PLP1 and Ig-
PLP-LR and described in Fig. 8, were measured and shown here along
with the responses to PLP1 peptide.1050 Broad T Cell Antagonism by Endocytic Presentation of a Peptide Analogue
mune disease. Both Ig-PLP1 and Ig-PLP-LR could be cap-
tured by rabbit antibodies to the synthetic peptides and bind
rat anti–mouse k mAb indicating peptide expression and
proper pairing of the heavy and light chains (Fig. 2). Ig-
PLP1 was presented to T cells in a specific manner indicat-
ing that the PLP1 peptide was released from the Ig and
bound class II I-As molecules (Fig. 3). In this case, the flank-
ing regions seem to have no interfering effect on the pre-
sentation of Ig-PLP1, as has been observed for other T cell
peptides expressed on proteins unrelated to their own envi-
ronment (32–35, 45, 46). The presentation of Ig-PLP1 was
100-fold better than free PLP1 peptide (Fig. 4). This obser-
vation parallels with results obtained with an IgG1 chimera
expressing a T cell peptide from l2 phage repressor protein
(35) and with Ig-HA (34). The efficacy of Ig-PLP1 in acti-
vating specific T cells is probably partly due to efficient in-
ternalization via FcR as we have previously seen for Ig-HA
(34). Moreover, since Ig-PLP1 is presumably, like Ig-HA,
processed in endocytic vacuoles, the released PLP1 peptides
access newly synthesized class II molecules and allow for the
formation of significant amounts of peptide–class II com-
plexes (36). Ig-PLP-LR is also taken up by APCs, pro-
cessed, and presented to T cells; otherwise it would not have
inhibited PLP1-mediated T cell stimulation. Indeed, when
APCs were incubated with PLP1 peptide in the presence
of Ig-PLP-LR, there was no activation of the PLP1-spe-
cific T cell hybridomas (Fig. 5 a). Ig-PLP-LR was much
more potent than free PLP-LR peptide in inhibiting PLP1-
mediated T cell activation indicating a better presentation
of the peptide when delivered on the Ig chimera as was the
case for PLP1. These results confirm the observation by
Vidal et al. (44) showing that efficient endocytic presenta-
tion of an antagonist peptide could outcompete an external
agonist and inhibit IL-2 production by specific T cells.
Furthermore, when the activation of T cells by native
PLP and Ig-PLP1 was carried out in the presence of graded
concentrations of Ig-PLP-LR, IL-2 production declined as
Ig-PLP-LR increased. However, free PLP-LR peptide
failed to inhibit T cell activation mediated by native PLP or
Ig-PLP1 (Fig. 5). A maximum of 50% inhibition in IL-2
production was seen when the activation of T cells by Ig-
PLP1 was carried out in the presence of Ig-W (Fig. 5 b).
Ig-PLP1 and Ig-W have an identical heavy chain constant
region and use the same FcR to internalize into APCs. There-
fore, Ig-W could outcompete Ig-PLP1 for internalization
and diminish the activation of T cells. Ig-W, had a similar
effect on the presentation of Ig-HA (34), but had no effect
on the activation of T cells by native PLP (Fig. 5 c).
Whereas free PLP-LR antagonized only activation me-
diated by free PLP1 peptide, the spectrum of antagonism
by Ig-PLP-LR broadens to include antigen requiring en-
docytic processing such as native PLP and Ig-PLP1 (Table 2).
Two lines of evidence indicated that the mechanism re-
sponsible for PLP-LR and Ig-PLP-LR–mediated inactiva-
tion of T cells was likely to be TCR antagonism rather
than blockage of class II molecules. At the extracellular
level, PLP2 peptide, which uses I-As class II molecules for
presentation (37), did not inhibit the activation of T cells
by free PLP1 peptide. At the endocytic level, Ig-PLP2,
which is presented by I-As, did not antagonize native PLP
for the activation of T cells. Competition for binding to
class II may take place. However, a living antigen present-
ing system, such as the one we used, and the design of our
experimental system are not suitable for optimal blockade
as demonstrated by the control experiments using PLP2
peptide and Ig-PLP2 chimera. Therefore, one can specu-
late that TCR engagement with PLP-LR-I-As complexes
on the surface of APCs antagonizes the cells rather than
stimulates them. If we retain this possibility, one may ex-
Table 1. Ig-PLP-LR but Not Free PLP-LR Peptide Mediates
T Cell Antagonism In Vivo
Mouse
Ig-PLP1 coadministered with
Ig-W Ig-PLP-LR PLP-LR peptide
PLP1/PPD*
%
1 100 28 81
29 5 4 0 9 1
37 8 3 7 9 3
4 79 25 100
Three groups of mice (four per group) were immunized with 50 mg Ig-
PLP1 mixed with 150 mg Ig-W; 50 mg Ig-PLP1 mixed with 150 mg Ig-
PLP-LR; and 50 mg Ig-PLP1 mixed with 100 mg PLP-LR peptide, re-
spectively. After 10 d, the lymph nodes were removed and 4 3 105 cells
were stimulated in vitro with 15 mg/ml PLP1 peptide, 15 mg PLP2
peptide, 5 mg/ml PPD, or media without stimulator and assayed for
[3H]thymidine incorporation as described in Materials and Methods.
The mean cpm obtained for media without stimulator was used as
background (BG).
*The indicated numbers represent percentage values of PLP1-specific
proliferation relative to PPD-specific proliferation and were estimated
as follows: (mean cpm of triplicates obtained with PLP1 stimulation 2
mean cpm triplicate BG) / (mean cpm of triplicates obtained with
PPD 2 mean cpm triplicate BG) 3 100. The percentage values of
PLP2-specific proliferation relative to PPD ranged between 0 and 15%
indicating the absence of significant proliferation to PLP2 peptide (used
as negative control).
Table 2. Ig-PLP-LR– and PLP-LR–mediated T Cell 
Antagonism In Vitro
Antagonist
Stimulator
PLP1 PLP Ig-PLP1
PLP-LR 12 2
Ig-PLP-LR 11 1
This summarizes the effect of PLP-LR and Ig-PLP-LR on IL-2 pro-
duction by PLP1-specific T cell hybridomas when they are stimulated
with APCs pulsed with Ig-PLP1, PLP1, or native PLP in the presence
of PLP-LR or Ig-PLP-LR.
1, inhibition of IL-2 production and therefore antagonism; 2, absence
of inhibition of IL-2 production and therefore no antagonism.1051 Legge et al.
plain the antagonism by Ig-PLP-LR as follows; because of
efficient presentation of Ig-PLP-LR in endocytic vaccuoles,
significant levels of PLP-LR–I-As complexes are generated.
The amount of complexes on the cell surface is propor-
tional to the amount of Ig-PLP-LR offered to the APCs.
When PLP1 stimulation is carried out in the presence of
Ig-PLP-LR, both PLP-LR–I-As and PLP1–I-As are present
on the surface of a given APC and increase in the concen-
tration of Ig-PLP-LR leads to higher number of PLP-LR–
I-As complexes. Considering that z3,500 TCRs have to
be engaged for a T cell to be activated (47), and that a
given complex of peptide–class II serially engages z200
TCRs (31), a T cell is antagonized when TCR engage-
ment with PLP-LR–I-As complexes override engagement
with PLP1–I-As. Overall, because of efficient loading of
PLP-LR by Ig-PLP-LR, T cell antagonism is achieved by a
higher frequency of serial triggering of TCR by PLP-LR–
I-As complexes. This is probably more conceivable when
Ig-PLP-LR is engaged in antagonizing native PLP or Ig-
PLP1, which are processed in endocytic vacuoles. How could
Ig-PLP-LR antagonize PLP1 peptide, a stimulator that may
not require processing but rather bind directly to cell sur-
face class II molecules? One possibility is that only a limited
number of PLP1–class II complexes could be generated be-
cause external PLP1 binds empty class II and/or displaces
other peptides from I-A molecules. These conditions may
limit the number of complexes that could be available for
stimulation. Another possibility is that the turnover of cell
surface MHC molecules contribute to a short stay of com-
plexes formed at the extracellular milieu (class II molecules
have been in the cell surface for some time before binding
the extracellular peptide), whereas complexes formed in the
endocytic compartment will reside for a normal period of
time because they have just been translocated to the cell
surface. This may also be the reason why PLP-LR could
not antagonize Ig-PLP1 or PLP but did antagonize PLP1
peptide. Considering recent findings that complexes made
of MHC–antagonist peptide engage the TCR for a shorter
period of time than those made of MHC–agonist peptide
(48), we lean to the possibility that external peptide forms
very few complexes with a short stay at the cell surface, and
endocytic processing is more effective for the generation of
MHC–peptide complexes that could trigger more TCR
because of longer residency at the cell surface. Overall, in-
ternalization via FcR of Ig chimeras and efficient endocytic
presentation may be responsible for the broad antagonism
by Ig-PLP-LR, and the formation of fewer short-lived
complexes, when the peptide is externally added to the
APCs, may be responsible for the inability of PLP-LR to
antagonize the endocytic presentation of PLP and Ig-PLP1.
Overall, this demonstrates for the first time that competi-
tion between agonist and antagonist at the endocytic level
is achievable, but this only occurs when the antagonist pep-
tide is efficiently presented within the endocytic compart-
ment.
In vivo, when Ig-PLP1 was injected subcutaneously in
the foot pads and at the base of the limbs and tail, routes
that mostly target the response to the lymph nodes, a strong
specific T cell response to PLP1 peptide was induced (Fig.
7). These results are expected considering that Ig-PLP1 was
efficient in presenting the peptide to T cells in vitro (Fig. 4)
and that Ig-HA has been shown to prime a strong HA-spe-
cific T cell response (34). However, interestingly there is a
significant PLP1-specific response detected in the spleen,
an organ that mostly filters and responds to systemic Ags
(Fig. 7 b). One possibility we can put forth to explain these
results is that Ig-PLP1, because of its long half life, was able
to circulate and reach both the lymphatic and blood circu-
lation and consequently be presented at both systemic and
lymphatic sites.
Although Ig-PLP1 was efficiently presented and induced
a strong in vivo T cell response, it was possible to antago-
nize such a response by Ig-PLP-LR (Fig. 8). Indeed, when
Ig-PLP1 was coadministered to mice with Ig-PLP-LR, the
response to PLP1 peptide was markedly reduced. This de-
cline in PLP1 response was specifically induced by Ig-PLP-
LR because when Ig-PLP1 was coadministered with Ig-W
instead of Ig-PLP-LR, the response to PLP1 was not af-
fected. Efficient in vivo endocytic presentation of Ig-PLP-
LR may be the fundamental basis for the decline in PLP1-
specific response. The failure of PLP-LR peptide to inhibit
Ig-PLP1–mediated T cell activation in vitro coupled with
the potency of Ig-PLP-LR in antagonizing Ig-PLP1 T cell
stimulation supports the belief that Ig-PLP-LR–mediated
in vivo antagonism may be related to efficient presentation.
Moreover, when free PLP-LR peptide was coadministered
with Ig-PLP1, there was no evidence for a decline of the
PLP1 response (Table 1). The lack of antagonist effect by
free PLP-LR peptide was not due to a net lower amount of
injected peptide because the mice were given z34-fold
more PLP-LR in the free peptide form than Ig-PLP-LR
form (on the basis of a molecular weight of 150,000 dal-
tons, the 150 mg Ig–PLP-LR given to the mice correspond
to 1 nmol of Ig that contains 2 nmol of PLP-LR peptide,
whereas with a molecular weight of 1,468 daltons, the 100 mg
of free PLP-LR peptide correspond to 68 nmol of peptide).
The mechanism by which Ig-PLP-LR reduced the re-
sponse to PLP1 is not clear. However, knowing that Ig-
PLP-LR induced PLP-LR–specific T cells (Fig. 9) when
it was coadministered with Ig-PLP1, it can be speculated
that these PLP-LR–specific T cells downregulate PLP1–
specific T cells (49). Although there was induction of PLP-
LR–specific response when free PLP-LR peptide was ad-
ministered with Ig-PLP1 (not shown), there was no evident
reduction in the proliferative response to PLP1. Further
studies are required to identify any qualitative differences
among T cells induced by Ig-PLP-LR and those induced
by PLP-LR peptide. Another possibility that could explain
the reduction in T cell response to PLP1 is in vivo antago-
nism by PLP-LR–MHC complexes. Ig-PLP1 and Ig-PLP-
LR have identical isotypes and could bind the same FcR
and internalize into the same APCs. Simultaneous presen-
tation of PLP-LR and PLP1 by the same APCs could, as is
seen in the in vitro assays, be responsible for the antago-
nism of PLP1-specific T cells by Ig-PLP-LR. The striking
features associated with this endocytic antagonist system are1052 Broad T Cell Antagonism by Endocytic Presentation of a Peptide Analogue
its high efficacy and its broad spectrum of activity against
free peptides and most importantly autoantigens which re-
quire endocytic processing. Indeed, our data demonstrate
for the first time that competition between agonist and an-
tagonist is achievable at the endocytic level and ensures
downregulation of autoreactive T cells, in vivo. Efficient
endocytic presentation of peptide analogues may operate
through mechanisms that could overcome the abundant
MHC–agonist complexes generated in spontaneous disease
subsequent to the eruption and continuous endocytic pre-
sentation of autoantigens.
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